#United States #Class Action #San Francisco #Aardvark Therapeutics #AARD

Aardvark Therapeutics Investors on Alert for Potential Class Action Lawsuit

Investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) are being informed about a pending class action lawsuit that presents an opportunity for those who experienced substantial financial losses. The national shareholder rights firm, Hagens Berman Sobol Shapiro LLP, is representing individuals who acquired the company's common stock following its initial public offering (IPO) and during a specified class period.

Understanding the Class Action Lawsuit

The lawsuit is structured around allegations that Aardvark misled investors about the safety and efficacy of its leading drug, ARD-101, which targets bitter taste receptors aimed at managing hyperphagia in Prader-Willi Syndrome (PWS). The claim notes that the company failed to disclose significant safety issues associated with the drug. Issues noted included adverse cardiac events that occurred during clinical trials, which were not disclosed to investors, ultimately leading to overstated clinical and commercial prospects for Aardvark.

On February 27, 2026, Aardvark announced that it would pause its Phase 3 HERO trial due to unexpected cardiac observations occurring at higher than intended dosages. This announcement led to a drastic 56% reduction in the company's stock price. Subsequently, on May 14, 2026, the company faced a full clinical hold from the FDA on its investigational new drug application for ARD-101, resulting in an additional 32.1% drop in stock value. Such events triggered concerns among investors, highlighting the potential for Aardvark to have breached securities laws by providing misleading information.

What Should Aardvark Investors Do?

Investors who purchased shares or were otherwise impacted during the specified class period are encouraged to come forward and participate in the class action. The deadline for investors to apply as lead plaintiffs in the case is October 13, 2026. Hagens Berman emphasizes the importance for class members to assess their legal rights and explore options for recovery given the financial fallout from Aardvark's developments.

The firm is actively investigating the claims and the circumstances surrounding Aardvark's disclosures and the fallout ensuing from its trial outcomes. Interested parties can reach out to Hagens Berman for more information regarding the investigation, or to participate.

Points of Contact

According to Reed Kathrein, a partner at Hagens Berman leading the investigation, the firm is willing to assist in addressing inquiries from affected investors. For those who may wish to provide insider information regarding Aardvark, the SEC’s Whistleblower program may offer monetary incentives for original information that leads to successful recoveries.

For direct inquiries, interested individuals may contact Hagens Berman at [email protected] or by calling 844-916-0895.

The unfolding situation at Aardvark Therapeutics highlights the risks associated with investing in clinical-stage biopharmaceutical companies, particularly regarding the authoritative ramifications once trials do not proceed as expected or when undisclosed safety issues are revealed. Investors are strongly urged to stay informed and consider consulting with legal experts to navigate this developing situation.

Conclusion

As the legal proceedings unfold, affected investors should proactively seek to understand their rights and avenues for holding Aardvark accountable for any misrepresentations made during the initial public offering and following announcements regarding its clinical trials. Aardvark’s ongoing saga serves as a crucial reminder of the inherent risks in investing in healthcare and biopharmaceutical sectors, particularly with drugs targeting complex health issues such as Prader-Willi Syndrome.